JPS63156727A - Remedy for dermatosis and adhesive plaster using said remedy - Google Patents
Remedy for dermatosis and adhesive plaster using said remedyInfo
- Publication number
- JPS63156727A JPS63156727A JP61301335A JP30133586A JPS63156727A JP S63156727 A JPS63156727 A JP S63156727A JP 61301335 A JP61301335 A JP 61301335A JP 30133586 A JP30133586 A JP 30133586A JP S63156727 A JPS63156727 A JP S63156727A
- Authority
- JP
- Japan
- Prior art keywords
- lysozyme
- cholic acid
- remedy
- adhesive plaster
- gauze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000017520 skin disease Diseases 0.000 title claims abstract description 12
- 239000000853 adhesive Substances 0.000 title claims abstract 5
- 230000001070 adhesive effect Effects 0.000 title claims abstract 5
- 239000011505 plaster Substances 0.000 title abstract 3
- 206010048768 Dermatosis Diseases 0.000 title abstract 2
- 102000016943 Muramidase Human genes 0.000 claims abstract description 29
- 108010014251 Muramidase Proteins 0.000 claims abstract description 29
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 29
- 229960000274 lysozyme Drugs 0.000 claims abstract description 29
- 239000004325 lysozyme Substances 0.000 claims abstract description 29
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 29
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 26
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004380 Cholic acid Substances 0.000 claims abstract description 24
- 229960002471 cholic acid Drugs 0.000 claims abstract description 24
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 24
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 10
- 150000003839 salts Chemical class 0.000 abstract description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 abstract description 5
- 102000002322 Egg Proteins Human genes 0.000 abstract description 5
- 108010000912 Egg Proteins Proteins 0.000 abstract description 5
- 235000014103 egg white Nutrition 0.000 abstract description 5
- 210000000969 egg white Anatomy 0.000 abstract description 5
- 210000000941 bile Anatomy 0.000 abstract description 4
- -1 lysozyme chloride Chemical class 0.000 abstract description 3
- 241000283690 Bos taurus Species 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 229940099352 cholate Drugs 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 239000011591 potassium Substances 0.000 abstract description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000004816 latex Substances 0.000 abstract 1
- 229920000126 latex Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000008223 sterile water Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、傷口等の治療に適した皮ふ疾患治療剤及びそ
れを使用した絆創膏に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a skin disease therapeutic agent suitable for treating wounds, etc., and a bandage using the same.
従来より、傷口の保護を行なうものとして絆創膏がある
が、従来の絆創膏はたんに滅菌したガーゼを粘着テープ
に貼付しただけのものであるので、傷口等の保護剤とは
なっても治療剤とは云えないものである。Traditionally, bandages have been used to protect wounds, but since traditional bandages are simply sterilized gauze affixed to adhesive tape, they are not used to protect wounds, etc., but are not considered therapeutic agents. cannot be said.
そこで従来よシ、傷口等の皮ふ疾患を簡便に治療するこ
とのできる治療剤の開発が望捷れている。Therefore, it is desirable to develop therapeutic agents that can easily treat skin diseases such as wounds.
本発明は、極くあシふれた天然物質を用いた皮ふ治療剤
を提供することを目的としてなされたものである。The present invention was made for the purpose of providing a skin treatment agent using extremely common natural substances.
本発明者は、この目的を達成せんと種々研究の結果リゾ
チームとコール酸を溶解させた水溶液は、傷口化膿萌で
あるブドウ球函を特異的に戴置する作用があることにヒ
ントを得、さらに研究の結果、本発明を完成させたもの
である。In order to achieve this objective, the present inventor conducted various studies and found that an aqueous solution in which lysozyme and cholic acid were dissolved had the effect of specifically placing grape bulbs, which are the cause of wound suppuration. As a result of further research, the present invention was completed.
本発明の皮ふ疾患治療剤はリゾチームとコール酸を有効
成分とすることを特徴とし、まだそれを使用した絆創膏
はりゾチームとコール酸を有効成分とする皮ふ疾患治療
剤を含浸させたガーゼを粘着性シートに装置してなるこ
とを特徴とするものである。ここでリゾチームとは卵白
やイチジク乳液中等から常法によシ抽出してえられる酵
素であり、等電点りゾチームのみで々く塩化リゾチーム
等のりゾチーム塩類も含む。通常卵白中のりゾチ−ムを
抽出し、結晶化してえられる結晶状のリゾチームの他、
結晶状の卵白リゾチームを微粉末化した粉末状リゾチー
ム等卵白起源のりゾチームが用いられる。The therapeutic agent for skin diseases of the present invention is characterized in that it contains lysozyme and cholic acid as active ingredients. This device is characterized by being installed on a sheet. Here, lysozyme is an enzyme obtained by extraction from egg white, fig milk, etc. by a conventional method, and includes not only isoelectrically focused lysozyme but also lysozyme salts such as lysozyme chloride. In addition to crystalline lysozyme, which is usually obtained by extracting and crystallizing lysozyme from egg white,
Egg white-derived lysozyme is used, such as powdered lysozyme that is obtained by pulverizing crystalline egg white lysozyme.
また、コール酸とは動物の胆汁中に含まれている酸であ
シ、牛の胆汁中には５〜６％のコール酸の含有率を示す
。尚、本発明においてはコール酸ナトリウムやコール酸
カリウム等のコール酸の塩類も用いることができ、した
がってこれらの塩類もコール酸に含まれるものとする。Further, cholic acid is an acid contained in animal bile, and bovine bile has a cholic acid content of 5 to 6%. In the present invention, salts of cholic acid such as sodium cholate and potassium cholate can also be used, and therefore these salts are also included in cholic acid.
本発明の皮ふ疾患治療剤は、絆創膏、ぬれガーゼ、軟膏
及びスプレー等の形態のものとすることができる。The skin disease therapeutic agent of the present invention can be in the form of a bandage, wet gauze, ointment, spray, or the like.
リゾチームとコール酸の配合量は、治療剤に用いる溶媒
、（滅菌水やアルコール類）に対してリゾチームは０．
０２％（重量％をいう。以下同様）以上、コール酸は０
．５％以上添加することが望ましい。両物質の添加量が
少なすぎると皮ふ疾患の原因である化膿菌を死滅させる
作用が弱くなシ、皮ふ疾患治療剤としてはふされしくな
くなる傾向にあるからである。The blending amount of lysozyme and cholic acid is 0.00% for the solvent used for the therapeutic agent (sterilized water or alcohol).
0.02% (referring to weight%. The same shall apply hereinafter) or more, cholic acid is 0.
．． It is desirable to add 5% or more. This is because if the amounts of both substances added are too small, the effect of killing Pseudomonas pyogenes, which is the cause of skin diseases, will be weak and the product will tend to be unsuitable as a therapeutic agent for skin diseases.
実施例１．（絆創膏）
滅菌水に、リゾチーム０．５重量部とコール酸０．５重
量部を溶解させた。Example 1. (Bandage) 0.5 parts by weight of lysozyme and 0.5 parts by weight of cholic acid were dissolved in sterile water.
得られた溶液を巾１５朋長さ４０叫の滅菌ガーゼに塗付
し、このガーゼの一面を巾２０祁長さ５０ｍｍの織布製
粘着テープに貼付し、他の一面を粘着テープと同じ大き
さのポリエチレン剥離フィルムで仮着し、傷口治療用絆
創膏を得た。The obtained solution was applied to a sterile gauze with a width of 15 mm and a length of 40 mm, one side of the gauze was attached to a woven fabric adhesive tape with a width of 20 mm and a length of 50 mm, and the other side was attached with a tape of the same size as the adhesive tape. It was temporarily attached with a polyethylene release film to obtain a bandage for wound treatment.
実施例２．（ぬれガーゼ）
アルコール濃度５０％のエタノール水溶液に、リゾチー
ム０．０２重量部とコール酸０．５重量部を溶解した。Example 2. (Wet gauze) 0.02 parts by weight of lysozyme and 0.5 parts by weight of cholic acid were dissolved in an aqueous ethanol solution with an alcohol concentration of 50%.
上記溶液中に巾６０謳長さ１２０ｍｍからなる滅菌ガー
ゼ１００枚を１００分間浸漬した抜取シ出し、水切シの
後紙と合成樹脂のラミネートからなる容器に充填・密封
し、皮ふ疾患治療用ぬれガーゼを得た。100 sheets of sterile gauze, each 60 mm in width and 120 mm in length, were immersed in the above solution for 100 minutes, taken out, drained, and then filled into a container made of paper and synthetic resin laminate and sealed. I got it.
以下、本発明の皮ふ疾患治療剤の作用を試験例をもって
証明する。Hereinafter, the effects of the therapeutic agent for skin diseases of the present invention will be demonstrated using test examples.
試験例１（ブドウ球菌の抗菌力テスト）次の８つの試験
液を用意した。Test Example 1 (Staphylococcus antibacterial activity test) The following eight test solutions were prepared.
対象区ｌ：滅菌水
同 ２：リゾチーム濃度０．５％の滅菌水量 ３：リゾ
チーム濃度０．０２％の滅菌水量 ４：コール酸濃度
０．５％の滅菌水量 ５：コール酸濃度 ０．０２％の
滅閑水テスト区１：リゾチーム濃度０．５％、コール酸
濃度０．５係の滅菌水
同 ２：リゾチーム濃度０．２５％、コール酸濃度０．
２５％の滅菌水
同 ３：リゾチーム濃度０．０５％、コール酸濃度０．
０５係の滅菌水
これとは別に、ブドウ球菌が１０ ′Ｎ１個／７ｄの濃
度分布になるように調整した寒天培地（ペプトン、肉エ
キス、食塩、メチレンブルーを含む）を８個用意した。Target area 1: Sterile water 2: Sterile water volume with lysozyme concentration 0.5% 3: Sterile water volume with lysozyme concentration 0.02% 4: Cholic acid concentration
Sterilized water volume of 0.5% 5: Sterile water with cholic acid concentration of 0.02% Test area 1: Sterile water with lysozyme concentration of 0.5% and cholic acid concentration of 0.5% 2: Lysozyme concentration of 0.25% , cholic acid concentration 0.
25% sterile water 3: Lysozyme concentration 0.05%, cholic acid concentration 0.
Sterile water for section 05 Separately, eight agar media (containing peptone, meat extract, salt, and methylene blue) were prepared so that the concentration distribution of staphylococci was 10'N1/7d.
そして、この寒天培地上にそれぞれ各別に、上記試験液
をＱ、４ ｒｎｌずつ重層して、抗菌力を測定したとこ
ろ表−１の結果が得られた。Then, Q, 4 rnl of each of the above test solutions were layered on the agar medium, and the antibacterial activity was measured, and the results shown in Table 1 were obtained.
表−１
尚、表中の抗菌力の数値は、ブドウ球菌の発育阻止部分
が青色となるので、その青色部分の距離（論）を測定し
たものである。Table 1 Note that the antibacterial activity values in the table are determined by measuring the distance between the blue areas, since the areas where growth of staphylococci are inhibited are blue.
試験例２（完治テスト）
仔豚（ケ９ツチングンミニブタ雄）の背部の表皮の毛を
カミソリでそシ落し、ここに直径５■の傷を４ケ所つけ
た。Test Example 2 (Completion Test) The hair on the epidermis of the back of a piglet (male mini pig) was shaved off with a razor, and four wounds with a diameter of 5 cm were made there.
次にこの偏部に、試験例１の対照区１、同２、同４、テ
スト区１の試験液を塗付したガーゼを各別に貼付して傷
が完治するまでの日数を観察したところ表２の結果が得
られた。尚、ガーゼは毎日新しいものと取シ替えた。Next, gauze coated with the test solutions of Control Groups 1, 2, 4, and Test Group 1 of Test Example 1 was applied to each of these uneven areas, and the number of days until the wound completely healed was observed. 2 results were obtained. The gauze was replaced with new one every day.
表−２
〔発明の効果〕
以上述べたように、本発明の皮ふ疾患治療剤及びそれを
使用した絆創膏は、リゾチームとコール酸を有効成分と
するので、傷口等の完治力に優れている。またリゾチー
ムとコール酸は天然物であるので、副作用がないという
利点も有する。Table 2 [Effects of the Invention] As described above, the therapeutic agent for skin diseases of the present invention and the bandage using the same contain lysozyme and cholic acid as active ingredients, and therefore have excellent ability to completely heal wounds, etc. Furthermore, since lysozyme and cholic acid are natural products, they also have the advantage of having no side effects.
Claims (2)
徴とする皮ふ疾患治療剤。(1) A therapeutic agent for skin diseases characterized by containing lysozyme and cholic acid as active ingredients.
治療剤を含浸させたガーゼを粘着性シートに装置してな
ることを特徴とする絆創膏。(2) An adhesive bandage comprising an adhesive sheet of gauze impregnated with a skin disease treatment agent containing lysozyme and cholic acid as active ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61301335A JPS63156727A (en) | 1986-12-19 | 1986-12-19 | Remedy for dermatosis and adhesive plaster using said remedy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61301335A JPS63156727A (en) | 1986-12-19 | 1986-12-19 | Remedy for dermatosis and adhesive plaster using said remedy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63156727A true JPS63156727A (en) | 1988-06-29 |
Family
ID=17895620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61301335A Pending JPS63156727A (en) | 1986-12-19 | 1986-12-19 | Remedy for dermatosis and adhesive plaster using said remedy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63156727A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04145019A (en) * | 1990-10-02 | 1992-05-19 | Dia Seiyaku Kk | Poultice containing lysozyme chloride |
| WO1998031372A1 (en) * | 1997-01-16 | 1998-07-23 | Dr. Kief Lizenz Verwertungs Gesellschaft Mbh | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
-
1986
- 1986-12-19 JP JP61301335A patent/JPS63156727A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04145019A (en) * | 1990-10-02 | 1992-05-19 | Dia Seiyaku Kk | Poultice containing lysozyme chloride |
| WO1998031372A1 (en) * | 1997-01-16 | 1998-07-23 | Dr. Kief Lizenz Verwertungs Gesellschaft Mbh | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
| US6407085B1 (en) | 1997-01-16 | 2002-06-18 | Horst Kief | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69433939T2 (en) | HEMOSTATIC PLASTER | |
| US7714183B2 (en) | Use of honey in dressings | |
| EP0025640B1 (en) | Film forming composition and uses thereof | |
| DE60306134T2 (en) | WUNDAUFLAGE CONTAINING AN OXIDOREDUCTASE ENZYME IN HYDRATED STATE | |
| Napavichayanun et al. | Inflammatory reaction, clinical efficacy, and safety of bacterial cellulose wound dressing containing silk sericin and polyhexamethylene biguanide for wound treatment | |
| CN105012993B (en) | A kind of cation Medical Living Creature Gum antiseptic dressing and preparation method thereof | |
| US4391799A (en) | Protective gel composition for treating white phosphorus burn wounds | |
| DE60101956T2 (en) | FOAMING Wound Bandage | |
| JPH0614956B2 (en) | Hydrophilic biopolymer copolyelectrolite | |
| EA010316B1 (en) | Wound dressing based on microbial-derived cellulose, use thereof and kit containing thereof | |
| US20080020025A1 (en) | Composition for wound care and method of using same | |
| CN106344956A (en) | Chitosan antibacterial gel with effect of promoting healing and method for preparing chitosan antibacterial gel | |
| JP3550685B2 (en) | Wound healing agent | |
| JP6290184B2 (en) | Wound dressing | |
| DE60312969T2 (en) | PREPARATION FOR WOUND HEALING AND PREVENTING THE POSSESSION OF ASSOCIATIONS TO THE WOUNDS | |
| CN114246976A (en) | Hydrogel dressing for wound inflammation diminishing and preparation method thereof | |
| HU200103B (en) | Process for producing pharmaceutical compositions for treating lack of epithelium | |
| RU2197273C2 (en) | Plaster-type device for local application of anticomedones composition and method of manufacturing the same | |
| RU2180856C1 (en) | Agent for wound healing | |
| RU2194535C2 (en) | Preparation for treating the wounds | |
| JPS63156727A (en) | Remedy for dermatosis and adhesive plaster using said remedy | |
| CN105536041A (en) | Royal jelly acid containing antibacterial biological dressings as well as preparation method and application thereof | |
| EP0260645A1 (en) | Therapeutic system for the local application of pharmaceutical compounds | |
| JP2003225298A (en) | Adhesive plaster | |
| JPS61100256A (en) | Preparation for gradually releasing iodine |